COLL

NASDAQ

Collegium Pharmaceutical Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2015

News25/Ratings12

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

News · 26 weeks43-50%

2025-10-262026-04-19

Mix2590d

Insider9(36%)
Other6(24%)
SEC Filings6(24%)
Earnings4(16%)

Latest news

25 items

17hPR
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2026 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Comp
15dPR
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare ConferenceFireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m. ETVirtual A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Piper Sandler Spring Biopharma SymposiumThursday, April 16, 2026Boston, MA About Collegium Pharmaceutical, Inc.Collegium is building
16dSEC
SEC Form DEF 14A filed by Collegium Pharmaceutical Inc.
DEF 14A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
16dSEC
Collegium Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
20dINSIDER
SEC Form 4 filed by Dieter David
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
28dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.
SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
34dINSIDER
SEC Form 4 filed by Dieter David
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
35dSEC
Collegium Pharmaceutical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
35dPR
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue – – Expected Patent Protection into 2037 – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan – – Conference Call Scheduled for Today at 9:00 a.m. ET – STOUGHTON, Mass. and CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) a
43dINSIDER
EVP & General Counsel Dieter David sold $228,110 worth of shares (6,224 units at $36.65), decreasing direct ownership by 6% to 91,047 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
49dINSIDER
EVP & Chief Commercial Officer Dreyer Scott sold $2,019,437 worth of shares (49,976 units at $40.41), decreasing direct ownership by 41% to 71,770 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
49dPR
Collegium to Present New Real-World Data at PainConnect 2026
STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium's pain portfolio and reflect the Company's continued focus on generating evidence that helps inform everyday practice. "Understanding how therapies perform in real-world settings is essential to informing pain treatment," said Thomas Smith, M.D., Chief Med
51dSEC
SEC Form 144 filed by Collegium Pharmaceutical Inc.
144 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
51dPR
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan – Credit: Ashley Osborn STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, an entrepreneur, musician, author, and advocate, announced today ‘Embrace Your Sparkle', a campaign aimed at encouraging broader understanding and open dialogue about at
52dPR
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026Miami, FL Jefferies Biotech on the Beach SummitTuesday, March 10, 2026Miami, FL The Citizens Life Sciences ConferenceTuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ETMiami, FL A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webc
56dSEC
SEC Form 10-K filed by Collegium Pharmaceutical Inc.
10-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
56dSEC
Collegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
56dPR
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents, and Marketable Securities of $386.7 Million – – Reaffirmed Full-Year 2026 Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Feb. 26,
59dPR
Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are working together to ensure that the club's home games are welcoming and sensory-inclusive for all fans. As part of the partnership, the Collegium Sensory Room will be available at Gillette Stadium and Centreville Bank Stadium in 2026, and White Stadium beginning in 2027, for all Boston Legacy FC home matches. The dedicated space will provide a quieter, more secure environment for gue
70dINSIDER
President and CEO Karnani Vikram was granted 111,795 shares and covered exercise/tax liability with 11,296 shares, increasing direct ownership by 103% to 197,864 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
70dINSIDER
EVP & General Counsel Dieter David was granted 31,199 shares and covered exercise/tax liability with 2,781 shares, increasing direct ownership by 41% to 97,271 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
70dINSIDER
EVP & Chief Commercial Officer Dreyer Scott was granted 49,725 shares and covered exercise/tax liability with 31,592 shares, increasing direct ownership by 18% to 121,746 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
70dINSIDER
EVP and Chief Medical Officer Smith Thomas B was granted 37,042 shares and covered exercise/tax liability with 17,435 shares, increasing direct ownership by 28% to 90,651 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
70dINSIDER
EVP & Chief Financial Officer Tupper Colleen was granted 59,155 shares and covered exercise/tax liability with 38,540 shares, increasing direct ownership by 16% to 147,282 units (SEC Form 4)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
70dPR
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q4 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available fo